Clinical Trial Update: A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating different doses of BI 764532 in DLL3-positive small cell lung cancer and other neuroendocrine tumors; the trial is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Small Cell Lung Cancer

Drugs mentioned

• BI 764532 (BI 764532)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Patients With Small Cell Lung Carcinoma and Other Neoplasms | Phase 1 | Status: RECRUITING